Nab-paclitaxel and carboplatin combined with antiangiogenic drugs
Published: 5 March 2020| Version 1 | DOI: 10.17632/vdhjxp87mh.1
Contributor:
Lili Mao
Description
We retrospectively investigated the efficacy and toxicity of NCA regimen in unresectable stage IIIC or IV melanoma patients who progressed on previous therapy. The NCA regimen consisted of nab-paclitaxel (260 mg/m2) and carboplatin(AUC=5) on day 1 and bevacizumab, 5 mg/kg IV every 2 weeks or endostatin 7.5mg/m2 days 1-14,Q28.